Funding for this research was provided by:
Text and Data Mining valid from 2018-10-03
Received: 7 June 2018
Accepted: 28 August 2018
First Online: 3 October 2018
Ethics approval and consent to participate
: The study was approved by the Regional Committee for Medical and Health Research Ethics, South-East Norway, and all patients gave written consent according to the Declaration of Helsinki.
: Not applicable.
: LT declares speakers fees from Roche, MSD, BMS, Pfizer, AbbVie, Novartis, and Janssen. MO declares research support and/or consultancy/speaker fees from Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Centocor, GSK, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Takeda, UCB, and Wyeth. HBH declares study grants from AbbVie/Pfizer and Roche. JS declares that he has no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.